Biggest Takeaway from Valeant (VRX) Call is 2017 Revs and EBITDA Expected to Be Below 2016 - Evecore ISI's Raffat

November 8, 2016 10:03 AM EST
Get Alerts VRX Hot Sheet
Price: $15.24 --0%

Rating Summary:
    10 Buy, 12 Hold, 4 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 4 | Down: 5 | New: 17
Trade VRX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Evecore ISI analyst Umer Raffat said by far the biggest takeaway from Valeant Pharma (NYSE: VRX) call is that 2017 revenues and EBITDA is expected to be below 2016. The CFO flagged generic competition against Isuprel, Virazole, Syprine, Mephyton etc.

Raffat said the single biggest question in his inbox: is 2017 EBITDA more like ~$4.2B or more like <$3.9B? "I asked mgmt a very specific question on the call with numbers and bridge into 2017, but we didn't hear hard numbers," he commented.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Umer Raffat

Add Your Comment